A review of multiple approaches towards an improved hepatitis B vaccine

Expert Opinion on Therapeutic Patents

Volumn 19, Issue 1, 2009, Pages 59-72

  Sanyal, Gautam ^a   Shi, Li ^b  

^a ASTRAZENECA   (United Kingdom)

^b GENZYME CORPORATION   (United States)

Author keywords

Adjuvant; Hepatitis B surface antigen (HBsAg); Hepatitis B vaccine (HBV vaccine); Hepatitis B virus (HBV); Immunomodulator; Vaccine formulation

Indexed keywords

ADEFOVIR; ALPHA INTERFERON; ALUMINUM HYDROXIDE; ALUMINUM PHOSPHATE; AS 04; CALCIUM PHOSPHATE; DNA VACCINE; ENTECAVIR; FAMCICLOVIR; FORMALDEHYDE; GANCICLOVIR; GLYCEROPHOSPHOLIPID; HEPATITIS A HEPATITIS B VACCINE; HEPATITIS B ANTIGEN; HEPATITIS B VACCINE; LAMIVUDINE; LOBUCAVIR; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINYLALANYL DIPALMITOYLPHOSPHATIDYLETHANOLAMINE; NUCLEOSIDE; PENCICLOVIR; PHOSPHOLIPID; PHOSPHORYL LIPID A; QUIL A; RECOMBINANT HEPATITIS B VACCINE; RECOMBIVAXHB; RIBAVIRIN; SAPONIN; UNCLASSIFIED DRUG; VIDARABINE; VIDARABINE PHOSPHATE; WRG 7128;

ADJUVANT THERAPY; ANTIBODY PRODUCTION; ANTIBODY TITER; ANTIGENICITY; CHILDHOOD; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG SAFETY; HEPATITIS A; HEPATITIS B; HUMAN; IMMUNOGENICITY; NONHUMAN; PATENT; REVIEW; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; ANIMALS; ANTIVIRAL AGENTS; CHILD; DRUG DESIGN; DRUG THERAPY, COMBINATION; HEPATITIS B; HEPATITIS B ANTIGENS; HEPATITIS B VACCINES; HUMANS; PATENTS AS TOPIC;

EID: 67649452372     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543770802587226     Document Type: Review

References (177)

1. Alter HJ, Blumberg BS. Further studies on a "new" human isoprecipitin system (Australia antigen). Blood 1966;27(3):297-309
2. Lai CL, Ratziu V, Yuen MF, Poynard T. Viral hepatitis B. Lancet 2003;362:2089-2094 (Pubitemid 38032767)
3. Chang MH. Hepatitis B virus infection. Semin Fetal Neonatal Med 2007;12(3):160-167 (Pubitemid 46670817)
4. Pungpapong S, Kim WR, Poterucha JJ. Natural history of hepatitis B virus infection: an update for clinicians. Mayo Clin Proc 2007;82(8):967-975 (Pubitemid 47206372)
5. Hilleman MR. Plasma-derived hepatitis B vaccine: a break-through in preventive medicine. In: Ellis RW, Marcel Dekker, editors, Hepatitis B vaccines in clinical practice. New York; 1979. p. 17-39
6. Szmuness W, stevens CE, zang EA, et al. A controlled clinical trial of the efficacy of the hepatitis B vaccine (Heptavax B):a final report. Hepatology 1981;1:377-385
7. Gretty RJ. Recombinant hepatitis b vaccines. In: Zuckerman AJ, Alan R Liss, editors, Viral hepatitis and liver disease. New York; 1988. p. 1017-1024
8. Merck & Co., Inc. PreS2+S hepatitis B vaccine derived from plasma US5030720; 1991
9. Sitrin RD, Wampler DE, Ellis RW. Survey of licensed hepatitis B vaccines and their production processes. In: Ellis RW, editor, Hepatitis B vaccines in clinical practice. Marcel Dekker, Inc., New York; 1993. p. 83-101
10. Stephenne J. Development and production aspects of a recombinant yeast-derived hepatitis B vaccine. Vaccine 1990;8(Suppl):S69-72 (Pubitemid 20154765)
11. Kniskern PJ, Miller WJ. Hepatitis B vaccines: blueprints for vaccines of the future. Biotechnology 1992;20:177-204
12. Keating, Gillian, Noble Stuart. Recombinant hepatitis B vaccine - a review of its immunogenicity and protective efficacy against hepatitis B. Drugs 2003;63:1021-1051 (Pubitemid 36575466)
13. Geier Mark R, Geier David A, Zahalsky Arthur C. A review of hepatitis B vaccination. Expert Opin Drug Saf 2003;2:113-122
14. Coates T, Wilson R, Patrick G, et al. Hepatitis B vaccines: an assessment of the seroprotective efficacy of two recombinant DNA vaccines. Clin Ther 2001;23:392-403 (Pubitemid 32328745)
15. Assad S, Francis A. Over a decade of experience with yeast recombinant hepatitis B vaccine. Vaccine 2000;18:57-67
16. Alper CA. The human immune response to hepatitis B surface antigen. Exp Clin Immunogenet 1995;12:171-181
17. Jilg W. Novel hepatitis B vaccines. Vaccine 1998;16:S65-8 (Pubitemid 29009801)
18. Zuckerman JN, Sabin C, Craig FM, et al. Immune response to a new hepatitis B vaccine in healthcare workers who had not responded to standard vaccine: randomised double blind dose-response study. BMJ Clin Res Ed 1997;314(7077):329-333 (Pubitemid 27056553)
19. Jones CD, Page M, Bacon A, et al. Characterization of the T- and B-cell response to a new recombinant pre-S1, pre-S2 and SHBs antigen containing hepatitis B vaccine (Hepagene); evidence for superior anti-SHBs antibody induction in responder mice. J Viral Hepat 1998;5(Suppl 2):5-8 (Pubitemid 28529883)
20. Zuckerman JN. Hepatitis B third-generation vaccines: improved response and conventional vaccine non-response - third generation pre-S/S vaccines overcome non-response. J Viral Hepat 1998;5(Suppl 2):13-15 (Pubitemid 28529885)
21. Ellis RW, Kniskern PJ, Hagopian A, et al. Preparation and testing of a recombinant-derived hepatitis B vaccine consisting of pre-S2 + S polypeptides. In: Zuckerman AJ, Alan R Liss, editors, Viral hepatitis and liver disease. New York; 1988. p. 1079-1086
22. Jones CD, Page M, Bacon A, et al. T-cell and antibody response characterization of a new recombinant pre-S1, pre-S2 and SHBs antigen-containing hepatitis B vaccine; demonstration of superior anti-SHBs antibody induction in responder mice. Vaccine 1999;17:2528-2537 (Pubitemid 29314445)
23. Katkov WN, Watkins E, Demelia HC, Dienstag JL. Immunogenicity of a "pre-S2 plus S" hepatitis B vaccine in healthy adults. J Viral Hepat 1994;1(1):79-83 (Pubitemid 2122921)
24. Thoelen S, Van Damme P, Mathei C, et al. Safety and immunogenicity of a hepatitis B vaccine formulated with a novel adjuvant system. Vaccine 1998;16(7):708-714 (Pubitemid 28172536)
25. Ambrosch F, Wiedermann G, Kundi M, et al. A hepatitis B vaccine formulated with a novel adjuvant system. Vaccine 2000;18:2095-2101 (Pubitemid 30129098)
26. Thoelen S, De Clercq N, Tornieporth N. A prophylactic hepatitis B vaccine with a novel adjuvant system. Vaccine 2001;19:2400-2403 (Pubitemid 32234248)
27. Jacques P, Moens G, Desombere I, et al. The immunogenicity and reactogenicity profile of a candidate hepatitis B vaccine in an adult vaccine non-responder population. Vaccine 2002;20:3644-3649 (Pubitemid 35223393)
28. Desombere I, Van Der Wielen M, Van Damme P, et al. Immune response of HLA DQ2 positive subjects, vaccinated with HBsAg/AS04, a hepatitis B vaccine with a novel adjuvant. Vaccine 2002;20:2597-2602 (Pubitemid 34615601)
29. Shi L, Caulfield MJ, Chern RT, et al. "Pharmaceutical and immunological evaluation of a single shot hepatitis B vaccine formulated with PLGA microspheres". J Pharm Sci 2002;91(4):1019-1035 (Pubitemid 34640927)
30. Lee HK, Park JH, Kwon KC. Double-walled microparticles for single shot vaccine. J Control Release 1997;44: p. 283-293 (Pubitemid 27039125)
31. Rao KVS, Panda SK, Manivel V. Macromolecular self-association of a synthetic peptide derived from the hepatitis B surface antigen: construction of a quaternary epitope. Vaccine 1992;10(4)204-208
32. Moynihan JS, D'Mello FIM, Howard CR. 48-mer synthetic peptide analogue of the hepatitis B virus "a" determinant induces an anti-HBs antibody response after a single injection. J Med Virol 2000;6:159-166
33. Engler OB, Dai WJ, Settle A, et al. Peptide vaccines against hepatitis virus: from animal model to human studies. Mol Immunol 2001;38:457-465 (Pubitemid 34008475)
34. Manivel V, Ramesh R, Panda SK, Rao KVS. A synthetic peptide spontaneously self-associates to reconstruct a group-specific, conformational determinant of hepatitis B surface antigen. J Immunol 1992;148(12):4006-4011
35. Manivel V, Tripathy A, Durgapal H, et al. A self-associating hepatitis B surface antigen-derived peptide that is immunogenic in alum. Vaccine 1993;11(3):366-371 (Pubitemid 23061182)
36. Lau GKK. Use of immunomodulatory therapy (other than interferon) for the treatment of chronic hepatitis B virus infection. J Gastroenterol Hepatol 2000;15(Suppl):E46-52 (Pubitemid 30435736)
37. Tsunoda I, Sette A, Fujinami RS, et al. Lipopeptide particles as the immunologically active component of CTL inducing vaccines. Vaccine 1999;17(7-8):675-685 (Pubitemid 29074721)
38. Benmohamed L, Gras-Masse H, Tartar A, et al. Lipopeptide immunization without adjuvant induces potent and long-lasting B, T helper, and cytotoxic T lymphocyte responses against a malaria liver stage antigen in mice and chimpanzees. Eur J Immunol 1997;275:1242-1253 (Pubitemid 27197230)
39. Vitiello A, Ishioka G, Grey HM, et al. Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection. I. Induction of a primary cytotoxic T lymphocyte response in humans. J Clin Invest 1995;95(1):341-349
40. Davis HL, Michel ML, Whalen RG. DNA-based immunization induces continuous secretion of hepatitis B surface antigen and high levels of circulating antibody. Hum Mol Genet 1993;2(11):1847-1851 (Pubitemid 23326610)
41. Davis HL, Mancini M, Michel ML, Whalen RG. DNA-mediated immunization to hepatitis B surface antigen: longevity of primary response and effect of boost. Vaccine 1996;14(9):910-915 (Pubitemid 26280933)
42. Gramzinski RA, Millan CL, Obaldia N, et al. Immune response to a hepatitis B DNA vaccine in Aotus monkeys: a comparison of vaccine formulation, route, and method of administration. Mol Med 1998;4(2):109-118 (Pubitemid 28223950)
43. Tacket CO, Roy MJ, Widera G, et al. Phase 1 safety and immune response studies of a DNA vaccine encoding hepatitis B surface antigen delivered by a gene delivery device. Vaccine 1999;17(22):2826-2829 (Pubitemid 29323008)
44. Wang S, Liu X, Fisher K, et al. Enhanced type I immune response to a hepatitis B DNA vaccine by formulation with calcium- or aluminum phosphate. Vaccine 2000;18(13):1227-1235 (Pubitemid 30001837)
45. Swain WE, Heydenburg-Fuller D, Wu MS, et al. Tolerability and immune responses in humans to a powderJect DNA vaccine for hepatitis B. Dev Biol 2000;104:115-119
46. Mumper RI, Ledebur HC Jr. Dendritic cell delivery of plasmid DNA. Applications for controlled genetic immunization. Mol Biotechnol 2001;19(1):79-95
47. Heijtink RA, Van-Bergen P, Van-Roosmalen MH, et al. Anti-HBs after hepatitis B immunization with plasma-derived and recombinant DNA-derived vaccines: binding to mutant HBsAg. Vaccine 2001;19(27):3671-3680 (Pubitemid 32522765)
48. Chen HB, Fang DX, Li FQ, et al. A novel hepatitis B virus mutant with A-to-G at nt551 in the surface antigen gene. World J Gastroenterol 2003;9(2):304-308 (Pubitemid 36215810)
49. Oon CJ, Chen WN, Zhao Y, et al. Detection of hepatitis B surface antigen mutants and their integration in human hepatocellular carcinoma. Cancer Lett 1999;136(1):95-99 (Pubitemid 29145219)
50. Milich DR, McLachlan A. The nucleocapsid of hepatitis B virus is both a T-cell-independent and a T-cell-dependent antigen. Science 1986;234:1398-1401 (Pubitemid 17210220)
51. Milich DR, Mclachlan A, Thornton GB, Hughes JL. Antibody production to the nucleocapsid and envelope of the hepatitis B virus primed by a single synthetic T cell site. Nature 1987;329:547-549 (Pubitemid 17124776)
52. Milich DR, Schodel F, Hughes JL, et al. The hepatitis B virus core and e antigens elicit different Th cell subsets: antigen structure can affect Th cell phenotype. J Virol 1997;71:2192-2201 (Pubitemid 27078599)
53. Papaevangelou G. Current combined vaccines with hepatitis B. Vaccine 1998;16:S69-72 (Pubitemid 29009802)
54. Fitzsimons D, Francois G, Emiroglu N, Van Damme P. Combined hepatitis B vaccines. Vaccine 2003;21:1310-1316 (Pubitemid 36263172)
55. Caufield MJ, Smith JG, Wang S, et al. Immunogenicity of a hexavalent combination vaccine in rhesus monkeys. Vaccine 2000;19:902-907
56. Frey S, Dagan R, Ashur Y, et al. Interference of antibody production to HBsAg in a combination hepatitis A/hepatitis B vaccine. J Infect Dis 1999;180:2018-2022
57. Leroux-Roels G, Moreau W, Desombere I, Safary A. Safety and immunogenicity of a combined hepatitis A and hepatitis B vaccine in young healthy adults. Scand J Gastroenterol 1996;31:1027-1031 (Pubitemid 26338302)
58. Amborsch F, Wiedermann G, Andre FE, et al. Clinical and immunological investigation of a combined hepatitis A and hepatitis B vaccine. J Med Virol 1994;44:452-456
59. Bruguera M, Bayas J-M, Vilella A, et al. Immunogenicity and reactogenicity of a combined hepatitis A and B vaccine in yong adults. Vaccine 1996;14(15):1407-1411 (Pubitemid 27008255)
60. Aristegui J, Dal-Re R, Diez-Delgado J, et al. Comparision of the reactogenicity and immunogenicity of a combined diphtheria, tetanus, acellular pertusis, hepatitis B, inactivated polio (DTPa-HBV-IPV) vaccine, mixed with the Haemophilus influenzae type b (hib) conjugate vaccine and adminidtered as a single injection, with the DTPa-IPV/Hib and hepatitis B vaccines administered in two simultaneous injections to infants at 2, 4, and 6 months of age, Vaccine 2003;21:3593-3600
61. Merck & Co. Inc. Method for improving culture medium for recombinant yeast. US6232111; 2001
62. Merck & Co.: Inc. Improved recombinant hepatitis B surface antigen. WO2000037104 ;2000
63. GlaxoSmithkline Biologicals SA. Purification of hbv antigens for use in vaccines. WO200212287; 2002
64. GlaxoSmithkline Biologicals SA. Novel vaccine. WO2003066094; 2003
65. Med. Tekhn. Mtkh. Stock Co. Method for preparing hepatitis B virus surface antigen, for use in a vaccine for immunization against hepatitis B, comprises culturing recombinant yeast cells Hansenula polymorpha. RU2205023; 2004
66. Dalian Kunyang Sci Tech Dev Co Ltd. Hepatitis B surface antigen and its application. CN1705962;2005
67. Chengdu Inst. of Biolog. Product. The complex granule of hepatitis B surface antigen containing front surface antigen S1, S2 and S immune determinants. WO2006069505; 2006
68. Univ Wuhan (CN). Yeast stain for preparing PreS-E1-E2 vaccine of hepatitis B and hepatitis C virus and preparation method thereof. CN1908157; 2007
69. Yamada T, Iwabuku H, Kanno T, et al. Physicochemical and immunological characterization of hepatitis B virus envelope particles exclusively consisting of the entire L (pre-S1+pre-S2+S) protein. Vaccine 2001;19:3154-3163 (Pubitemid 32324044)
70. Meiji Milk Prod. Co. Ltd. High rate production of hepatitis B surface antigen, comprises cultivating cell from human liver cancer tissue in culture solution and adding dexamethasone and N, N-dimethylacetamide to supernatant liquid. JP2001269194; 2002
71. Inst. Genetics Chinese Acad. Sci. Production of oral vaccine and antibiotic peptide active matter by using transgenic saline algae. CN1329169; 2002
72. Sunil Kumara GB, et al. Expression of hepatitis B surface antigen in potato hairy roots. J Plant Sci 2005;12:015
73. Smith M, Keegan M, Mason H, et al. Factors important in the extraction, stability and in vitro assembly of the hepatitis B surface antigen derived from recombinant plant systems. Biotechnol Prog 2002;18:538-550 (Pubitemid 34623229)
74. Huang Z, Elkin G, Maloney B, et al. Virus like particle expression and assembly in plants: hepatiris B and Norwalk viruses. Vaccine 2005;23:1851-1858 (Pubitemid 40331858)
75. mpson Boyce Plant Res; Health Research Inst. Expression of immunogenic hepatitis B surface antigens in transgenic plants. WO2000037610; 2000
76. Tianchong Bio Pharmacy Inst (CN). Method for constituting genetically engineered cell strain and bacterial strain for vaccine of hepatitis B. CN1317571; 2001
77. Virus Prevention And Control S (CN). Technique for purifying engineering fusion antigen of containing S (main protein) and previous SI (large protein) hepatitis B surface gene. CN1796417; 2007
78. Dvorah Diminsky, Reinhold Schirmbeck, Jorg Reimann, Yechezkel Barenholz. Comparison between hepatitis B surface antigen (HBsAg) particles derived from mammalian cells (CHO) and yeast cells (Hansenula polymorpha):composition, structure and immunogenicity. Vaccine 1997;15(6-7):637-647 (Pubitemid 27240478)
79. Sekisui Chemical Co., Ltd.; Marine Biotech Inst Co. Ltd. Preparation method for virus antigen. JP2000249704; 2000
80. Chiron Corp. Expressing hepatitis B virus surface antigen for vaccine preparation. WO2006113528; 2006
81. Novartis Vaccines & Diagnostic. Manufacture of vaccines that contain both hepatitis b virus surface antigen and surfactant. WO2007054820; 2007
82. Inst of Microbiology Chinese. Hepatitis B virus (HBV) antigenic polypeptide-heat shock protein complex and use thereof. WO2002014370; 2002
83. Stressgen Biotechnologies Corp. Hepatitis B virus treatment. WO2002062959; 2002
84. Univ. Glasgow. Hepatitis B testing. WO2000042194; 2000
85. Coleman, Paul F, Mushahwar, Isa K. Hepatitis b virus surface antigen mutant and methods of detection thereof. US2002177124; 2002
86. Health Research Institute. Method of immunizing against hepatitis B virus. US6319501; 2001
87. Chengdu Inst. of Biolog. Product. Fusion gene of hepatitis B surface antigen with carboxyl end having pres2 immune determinant and the protein thereof. WO2005116218; 2005
88. Page M, Friede M, Schmidt AE, Stober D. Stabilized HBC chimer particles as therapeutic vaccine for chronic hepatitis. US20040156863; 2004
89. Apovia, Inc. Stabilized immunogenic HBC chimer particles. WO2004053091; 2004
90. Lyons K, Birkett AJ, Haron JA. Stabilized immunogenic HBC chimer particles. US20040146524; 2004
91. Birkett AJ. Immunogenic HBC chimer particles stabilized with an n-terminal cysteine. US20030185858; 2003
92. Birkett AJ. Influenza immunogen and vaccine. US20030202982; 2003
93. Apovia, Inc. Immunogenic avian HBC chimer particles having enhanced stability. WO2003072722; 2003
94. Univ Fudan (CN). Application of hepatitis B surface antigen-antibody complexes in preparing prophylaxis product with no response or low response to hepatitis B vaccine. CN1919341; 2007
95. Donnelly JJ, Ulmer JB, Liu MA. DNA vaccines. Life Sci 1997;60 (3):163-172
96. Tacket CO, Roy MO, Widera G, et al. Phase 1 safety and immune response studies of a DNA vaccine encoding hepatitis B surface antigen delivered by a gene delivery device. Vaccine 1999;17:2826-2829 (Pubitemid 29323008)
97. Rottinghaus ST, Poland GA, Jacobson RM, et al. Hepatitis B DNA vaccine induces protective antibody responses in human non-responders to conventional vaccination. Vaccine 2003;4604-4608 (Pubitemid 37315782)
98. PowderMed's therapeutic DNA vaccine for chronic hepatitis B enters phase I clinical trials in patients. Innovations Report 30 March 2006
99. Merck & Co, Inc. Polynucleotide vaccine formulations. WO2000002591; 2000
100. Powderject Vaccines, Inc. Adjuvanted genetic vaccines WO2001032208; 2001
101. Hospital No. 458, PLA: Dual-plasmid gene vaccine resisting against hepatitis B virus, and its preparing process and application. CN1316518; 2001
102. Lipoxen Ltd., Liposome-entrapped dna oral vaccines. WO2001024773; 2001
103. Institute Pasteur. Method for immunization against hepatitis B. US6429201; 2002
104. University Of Massachusetts. Hepatitis B core antigen nucleic acid vaccine. US2001001098; 2001
105. Powderject vaccines. Nucleic acid constructs. US6881723; 2005
106. Wisconsin Alumni Research Foundation & Powderject Vaccines, Inc. Vaccination method for efficient induction of cytotoxic t lymphocyte response. WO200040261; 2000
107. PLA Second Medical University. A Hepatitis B DNA vaccine. CN1389268;2003
108. Univ First Hospital Jilin. Chimeric antigen gene of hepatitis B and hepatitis C and its nucleic acid vaccine. CN1690206; 2005
109. Mudroch DL, Goa K, Figgit DP. Combined Hepatitis A and B vaccines: a review of their immunogenicity and tolerability. Drugs 2003;63:2625-2649
110. Smithkline Beecham Biologicals. Novel composition. WO199905677; 1999
111. Smithkline Beecham Biological. Novel composition. US20030049268; 2003
112. Viella A, Dal-Re R, Simo D et al. Reactogenicity profile of a combined hepatitis A and B vaccine in clinical practice: a naturalistic study in adult travelers. Vaccine 2005;23:2465-2469 (Pubitemid 40332517)
113. Glaxo Smithkline Biologicals. Vaccine composition. WO2002000249; 2002
114. Green Cross Vaccine Co, Ltd. Quadrivalent combination vaccine including diphtheria toxoid, tetanus toxoid, whole cell pertussis and hepatitis B surface antigen, and preparation method thereof. WO2002005846; 2002
115. Smithkline Beecham Biologicals. Vaccine composition WO2002080965; 2002
116. Kim KW, Ji HJ, Lee YK, et al. Manufacturing method of combined vaccine. US20040048336; 2004
117. Smithkline Beecham Biologicals. Combined vaccine compositions. WO199945957; 1999
118. Smithkline Beecham Biologicals. Novel composition. WO2001017550; 2001
119. Smithkline Beecham Biologicals. combination vaccine for administration to adolescents. US7101560; 2006
120. Smithkline Beecham Biologicals. Vaccine against HBV and HPV. US7371390; 2008
121. GlaxoSmithkline Biologicals. Vaccine against HPV. EP1410805; 2005
122. Wheeler CM, Bautista ON, Tomassini JE, et al. Protocol 11 study investigators: safety and immunogenicity of co-administered quadrivalent human papillomavirus (HPV)-6/11/16/18 L1 virus-like particle (VLP) and hepatitis B (HBV) vaccines. Vaccine 2008;26(5):686-696
123. Chiron Corp. HBV/HCV virus-like particle. US6740323; 2004
124. Chiron Corp. HBV/HCV virus-like particle. EP1535628; 2005
125. Aktsionernoe Obschestvo Zakryt, Perm N Provizv Ob Biomed. Combined vaccine for immunoprophylaxis against viral hepatitis B and D, tetanus, diphtheria and pertussis WO2000007623; 2000
126. Aktsionernoe Obschestvo Zakryt, Perm N Provizv Ob Biomed. Combined vaccine for immunoprophylaxis against viral hepatitis B, tetanus and diphtheria. WO2000006197; 2000
127. Chiron Srl. Combination vaccines with whole cell pertussis antigen. WO2006097851; 2006
128. Smithkline Beecham Biologicals. Novel treatment. WO2000041463; 2000
129. Tripeptide. Vaccines containing ribavirin and methods of use thereof. WO2002013855; 2002
130. Chiron Corp. Method for treating chronic hbv infection. WO2000078343; 2000
131. Adelaide Res & Innovation Pty. Combination treatment WO2006133497; 2006
132. Smithkline Beecham Biologicals. Novel composition. WO200117550; 2001
133. Smithkline Beecham Biologicals. Novel composition. WO200117551; 2001
134. Smithkline Beecham Biologicals. Novel composition. WO199956772; 1999
135. Smithkline Beecham Biologicals. Novel composition. US2003049268; 2003
136. Desombre I, Wielden Mv D, Damme PV, et al. Immune response of HLA DQ2 positive subjects vaccinated with HBsAg/ASO4, S hepatitis B vaccine with a novel adjuvant. Vaccine 2002;20:2597-2602
137. Jaques P, Moens G, Desombre I, et al. The immunogenicity and reactogenicity profile of a candidate hepatitis B vaccine in an adult vaccine non-responder population. Vaccine 2002;20:3644-3649 (Pubitemid 35223393)
138. Smithkline Beecham Biologicals. Oil in water emulsions containing saponins. WO199911241; 1999
139. Smithkline Beecham Biologicals. Adjuvant systems and vaccines WO2000023105; 2000
140. Smithkline Beecham Biologicals. vaccines WO2000062800; 2000
141. Ottawa Health Research Institute & Coley Pharmaceutical Group. Immunostimulatory Nucleic Acids For Inducing A Th2 Immune Response WO200195935; 2001
142. Glaxo Group Limited. Novel compositions WO2004052909; 2004
143. Lim SG. Heplisav™: a new hepatitis B vaccine. Future Virol 2008;3:109-117
144. Changchun Huapu Biotechnology. CPG single-strand deoxynucleotides for use as adjuvant. WO2006056142; 2006
145. University College London. Micelle-forming lipopeptides targeted at antigen presenting cells useful as vaccine adjuvants. WO2001047553; 2001
146. Biomira Inc. Vaccine for modulating between T1 and T2 immune responses. WO2002076485; 2002
147. Eurodiagnostica. Peptide mixture and vaccine against a chronic viral infection. WO2001016163; 2001
148. Epimmune Inc. Compositions and methods for eliciting CTL immunity. US6419931; 2002
149. Epimmune Inc. HLA-restricted hepatitis B virus CTL epitopes US6322789; 2001
150. Epimmune Inc. Inducing cellular immune responses to hepatitis B virus using peptide and nucleic acid compositions. US6689363; 2004
151. Epimmune Inc. Inducing cellular immune responses to hepatitis B virus using peptide and nucleic acid compositions WO200219986; 2002
152. Chongqing Jiachen Bioengineering Co. Ltd; Inst Immunology. Immunogen for preparation of therapeutic vaccines or drugs for treatment of hepatitis B and the producing method and use thereof. WO2004026899; 2004
153. Korea Res Inst Bioscience & Biotechnolog. A Novel antigenic peptide sequence for the Hepatitis B virus vaccine. KR2004026367; 2004
154. Dobeel Corp. Pre-S protein of hepatitis B virus (HBV) as an adjuvant and a component of hbv vaccine WO2002094866; 2002
155. CSL Ltd. Immunogenic complexes and methods relating thereto WO200048630; 2000
156. Rhein Biotech Proz & Prod Gmbh. Vaccines comprising truncated HBC core protein plus saponin-based adjuvant EP1764369; 2007
157. Immunovaccine Technologies Inc. Vaccines with enhanced immune response and methods for their preparation US2002110568; 2002
158. Aventis Pasteur. Use of an amphipathic compound for providing an adjuvant to a subunit vaccine US6472159; 2002
159. NASVAX Ltd. Sphingoid polyalkylamine conjugates for hepatitis B virus vaccination US20060171956; 2006
160. Berna Biotech AG. Virosome particles comprising antigens from influenza virus and Hepatitis B virus. EP1652914; 2006
161. Berna Biotech. AGWO new class of virosome particles. 2006045532; 2006
162. Boyce Thompson. Institute for plant research at cornell & health research institute. WO20037610; 2003
163. Schweiz Serum & Impfinst Bern Pharmaceutically. Active composition and dispensing device. WO200027430; 2000
164. Cigb preparations containing virus-like particles as immunopotentiators administered through the mucosa. WO200032229; 2000
165. Cent Ing Genetica & Biotechnologica. Hepatitis B virus surface antigen as a mucosal immunostimulator and the resulting formulations. WO2003061692; 2003
166. Biomedical research models methods for tailoring the immune response to an antigen or immunogen. WO2005067966; 2005
167. Oral Vaccine Technologies Inc. Methods for tailoring the immune response to an antigen or immunogen. US2006035853; 2006
168. Powderject Vaccines, Inc. Powder compositions. WO2001093829; 2001
169. Velders MP, Schreiber H, Kast WM. Active immunization against cancer cells: impediments and advances. Semin Oncol 1998;25 (6):697-706 (Pubitemid 28565549)
170. Bocchia M, Bronte V, Colombo MP, et al. Antitumor vaccination: where we stand. Haematologica 2000;85(11):1172-1206
171. Chimigen ™. Hepatitis B therapeutic vaccines. Available from: http://www.virexx.com/Default.aspx?id=13
172. Techno Network Shikoku Co. Ltd. Dendritic cell obtained by antigen pulsing. WO2005097976; 2005
173. Techno Network Shikoku Co. Ltd. Dendritic cell obtained by antigen pulsing. WO2005100547; 2005
174. Buti M, Mas A, Prieto M, et al. A randomized study comparing lamivudine monotherapy after a short course of hepatitis B immune globulin (HBIg) and lamivudine with long-term lamivudine plus HBIg in the prevention of hepatitis B virus recurrence after liver transplantation. J Hepatol 2003;811-817 (Pubitemid 36613348)
175. Sanchez-Fuyeo A, Rimola A, Grande L, et al. Hepatitis B immunoglobulin discontinuation followed by hepatitis B virus vaccination:a new strategy in the prophylaxis of hepatitis B virus recurrence after liver transplantation. Hepatology 2000;31:496-501 (Pubitemid 30078618)
176. Angelico M, Paolo DD, Trinito MO, et al. Failure of a reinforced triple course of hepatitis B vaccination in patients transplanted for HBV-related cirrhosis. Hepatology 2002;35:176-181 (Pubitemid 34032558)
177. Bienzle U, Gunther M, Neuhaus R, et al. Immunization with an adjuvant hepatitis B vaccine after liver transplantation for hepatitis B-related disease. Hepatology 2003;38:811-819 (Pubitemid 37221664)